Tag: Lonza

Emerald and Lonza to Develop CBD cGMP-Standard Drug for MS

Patented new chemical entity derived from synthetic cannabidiol will initially target multiple sclerosis and scleroderma. Emerald Health Pharmaceuticals and Lonza have announced an agreement for th...

Lonza and Portola Started Supply of Second-Gen Andexxa

FDA green light of Portola's Prior Approval Supplement (PAS) for second-gen Andexxa follows tie-up with Lonza to develop the manufacturing process. Following the recent U.S Food and Drug Administra...

Lonza Reaches Milestone with Takeda

Lonza has reached a major milestone in its multiproduct partnership with Takeda Pharmaceutical Co. Takeda was granted marketing authorization by the European Commission for ALUNBRIG (brigatinib) as a ...

Lonza to set up a new biologics facility using GE Healthcare’s platform

test tube
Lonza (Switzerland) announced an agreement with GE Healthcare (USA) under which GE Healthcare will deliver a biologics facility to Lonza in Guangzhou (China).

Lonza launches its Collaborative Innovation Center in Israel

Lonza Pharma & Biotech officially opens its Collaborative Innovation Center (CIC) in the Haifa Life Science Park (Israel).

Lonza and Sartorius Stedim Biotech update their partnership

Lonza (Switzerland) and Sartorius Stedim Biotech (Germany) announced that they have modified their current agreement for supply of cell culture media by mutual accord.

Lonza’s Singapore facility to manufacture novel therapeutic antibody

Lonza and TRACON Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer.

Lonza buys Octane Biotech to develop autologous technology

The increase in equity share will allow Lonza to further develop the technology to support the growing need for scalable autologous manufacturing.

Lonza launches its new HPAPI suites in Switzerland

Lonza (Switzerland), a specialty CDMO, announced an expansion of its highly potent API (HPAPI) capacity for the specific support of antibody drug conjugate (ADC) payload manufacturing. This latest ...

Lonza initiated a pharmaceutical early-intermediates supply initiative

lonza building
The initiative leverages chemical production facilities at the company’s Visp (Switzerland) site to address increasing global early-intermediates supply security and quality concerns.

Lonza expands its Capsugel R&D offering

Capsule Delivery Solutions, part of Lonza Pharma & Biotech, is launching the Capsugel® Colorista™ product, a high-quality capsule based on an “all-colorants” formulation.

Lonza Bioscience launches a new bioresearch website

Lonza Bioscience, one of the leading suppliers to the the pharmaceutical, biotech and specialty ingredients markets, launches its new dedicated website.

Lonza announced a distribution agreement with Innosieve Diagnostics

Lonza Pharma & Biotech and Innosieve Diagnostics announced an exclusive distribution agreement for rapid bioburden testing technology.

Lonza became CAR-Treg cellular product manufacturer for TxCell

lonza building
TxCell and Lonza entered into a Master Service Agreement for the manufacture of TxCell’s HLA-A2 CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation.

Lonza will host a webinar focused on CRISPR technology

Today, CRISPR/Cas9 has emerged as the genome editing method of choice in research and biotechnology. Compared to other gene editing technologies, it is simpler to re-engineer, easier to use, and can target multiple sites.

Lonza invests in expansion of its US facility

Lonza Pharma & Biotech announced the investment in a new phase of development at their Portsmouth (New Hampshire, USA) site. The expansion will include mid-scale mammalian capacity and the addition of new cell-therapy suites.